When a Breakthrough Pancreatic Cancer Drug Hits the Market, Insurance Still Plays Catch‑up

When the FDA announced last month that it had cleared Revolution Medicines’ drug Rasonque for pancreatic cancer, the oncology world let out a collective sigh of relief. The medication, whose trials showed a near‑doubling of median overall survival, felt like a long‑awaited lifeline for a disease that kills more than 50,000 Americans each year.

For Kelsey Solano, a critical‑care nurse from Washington state, the news was anything but simple. Her husband Juan had been battling metastatic pancreatic cancer for over a year, and she had been navigating the drug’s expanded‑access program—often called compassionate use—when the FDA’s green light arrived.

"We were in the middle of the program, and suddenly it shut down," Kelsey recalls, the anxiety evident in her voice. The program, set up by Revolution Medicines to let patients obtain Rasonque before formal approval, was the only realistic route for families like theirs. Once the drug became officially approved, the manufacturer was obliged to close that pathway, assuming commercial insurance would swoop in.

But insurance didn’t move that fast.

Commercial payers and Medicare’s Part D plans need weeks, sometimes months, to write the code, set up pricing agreements, and establish prior‑authorization processes. In that waiting period, patients who are already sicker than most can’t afford to pause treatment.

Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network (PanCAN), sums up the frustration: "We keep hearing from families stuck on the waitlist for expanded access or newly diagnosed patients who can’t get the drug because their insurers haven’t caught up yet."

At St. Luke’s University Health Network in Pennsylvania, hematologist‑oncologist Arturo Loaiza‑Bonilla ran into the problem first‑hand. A Medicare beneficiary was denied coverage with a letter stating Rasonque "is not properly listed with the FDA and does not meet the regulatory requirements for a Part D‑eligible drug." Loaiza‑Bonilla posted the baffling denial on X, prompting a quick call from the pharmacy‑benefit manager, OptumRx, which then approved the prior‑authorization.

"It felt like they were taking their sweet time," he said, pointing to the broader lag that many of his patients still endure.

Juan’s journey underscores the stakes. Diagnosed with stage 3 disease in January 2025, he underwent an Appleby Procedure—a complex operation that can be curative for a minority of patients. After a successful surgery and a stint on FOLFIRINOX, doctors declared him disease‑free in November. Two months later, a scan revealed stage 4 spread to the liver, bile duct and peritoneum.

He entered a clinical trial at the Fred Hutchinson Cancer Center, receiving an experimental BridgeBio Oncology agent that temporarily slowed the tumor. By the time the trial ended, his disease had progressed again, and the prospect of Rasonque arrived just as the last line of treatment was fading.

"Seeing the data on Rasonque gave us a glimmer of real hope," Kelsey says, remembering the moment they learned the drug could double survival. Yet that hope quickly ran into bureaucracy.

Other patients across the country report similar stories: letters from insurers stating the drug isn’t yet on the formulary, endless phone calls to pharmacy‑benefit managers, and weeks spent waiting for a prior‑authorization number that might never come.

Experts argue the system needs a smoother hand‑off. "Regulatory approval should trigger an automatic bridge to coverage," suggests Dr. Anita Patel, an oncology policy analyst. "Otherwise we’re turning a scientific triumph into a cruel waiting game for people who can’t afford delays."

In the meantime, families like the Solanos are left juggling appeals, private funding, and the gut‑wrenching uncertainty of whether tomorrow’s treatment will be on the table. Their story is a stark reminder that a drug’s journey from lab bench to bedside is only half the battle; the insurance maze can be the final, most treacherous obstacle.